 2. 614 weeks and 9 months The study will enroll 152 healthy Nepalese infants in each treatment arm 304 in total. Demographic and clinical data will be collected on an electronic case report form to allow monitoring remotely. Participants will receive the study vaccine according to their allocated treatment arm in addition to their other routine vaccines. The investigators will collect 3 blood samples for analysis of serum antibody responses to the PCV10 vaccine serotypes throughout infancy see Table 1. The data collected will be analysed in order to determine whether the 610 schedule is non-inferior to the 614 schedule in generating immune responses against the vaccine serotypes above the 035μgmL threshold. These data will then be used to inform decision-making around augmenting the currently recommended 614 schedule to a 610 schedule in Nepal. The investigators will collect a nasopharyngeal swab at 2 time points to look at carriage of pneumococcus over time and to assess differences between the 2 groups. This is of critical importance because much of the programmatic impact of PCV is ultimately conferred by reductions in carriage at the community level and indirect effects resulting from that NP protection. 